Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Henry Schein (HSIC) Buys ABASE, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.
Will Envision Healthcare's Growth Strategies Help the Stock?
by Zacks Equity Research
Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.
Universal Health Grows Inorganically, Rising Costs a Drag
by Zacks Equity Research
Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.
Cerner Gains Momentum in HCIT Space Amid Tough Competition
by Zacks Equity Research
Cerner (CERN) continues to benefit from the ongoing demand for its core solutions and services driven by the HITECH Act.
Abaxis Well Poised on Solid Prospects, Competition Rife
by Zacks Equity Research
Abaxis' (ABAX) new sales and marketing strategies boost investors' confidence.
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Positive tidings on the regulatory front drive IRadimed's (IRMD) growth. The company's solid guidance is also encouraging.
4 Reasons Why Envision Healthcare (EVHC) Looks Dull
by Zacks Equity Research
Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.
Amedisys (AMED) Banks on Personal Care Amid Margin Woes
by Zacks Equity Research
Amedisys' (AMED) efforts have helped turn around the Personal Care business.
Envision Healthcare Down More Than 50% This Year, Here's Why
by Zacks Equity Research
Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Why Envision Healthcare (EVHC) Could Be Positioned for a Slump
by Zacks Equity Research
Envision Healthcare (EVHC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
by Zacks Equity Research
Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.
Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.
Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
What's in Store for Madrigal (MDGL) This Earnings Season?
by Zacks Equity Research
Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
by Zacks Equity Research
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Envision Healthcare Continues to Expand Physician Services
by Zacks Equity Research
Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.
Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now
by Zacks Equity Research
The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
by Zacks Equity Research
STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.
Here's Why You Should Invest in Orthofix International Now
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.
Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.
Omnicell (OMCL) Gains on Product Launches, Global Expansion
by Zacks Equity Research
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.